Published in Proteomics on December 01, 2008
A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. Proteomics (2011) 1.02
High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. PLoS One (2011) 0.99
Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br J Cancer (2009) 0.82
Complementary serum proteomic analysis of autoimmune hepatitis in mice and patients. J Transl Med (2013) 0.80
Human Urine Proteomics: Analytical Techniques and Clinical Applications in Renal Diseases. Int J Proteomics (2015) 0.76
PGRMC1 Is a Novel Potential Tumor Biomarker of Human Renal Cell Carcinoma Based on Quantitative Proteomic and Integrative Biological Assessments. PLoS One (2017) 0.75
Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics. Sci Rep (2015) 0.75
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol (2004) 5.84
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res (2006) 2.87
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res (2013) 2.45
Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology (2007) 2.45
Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics (2004) 2.43
Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics (2003) 2.17
Primary nonoperative treatment of displaced lateral fractures of the clavicle. J Bone Joint Surg Am (2004) 1.69
Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics (2005) 1.69
Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation. Kidney Int (2013) 1.61
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res (2009) 1.49
Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem (2005) 1.46
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Orientation changes of the myosin light chain domain during filament sliding in active and rigor muscle. J Mol Biol (2002) 1.42
Factor analysis of the Hospital Anxiety and Depression Scale from a large cancer population. Psychol Psychother (2002) 1.40
Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using western blotting. J Pathol (2009) 1.38
A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet (2011) 1.34
Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci (2004) 1.29
Banking of biological fluids for studies of disease-associated protein biomarkers. Mol Cell Proteomics (2008) 1.27
Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res (2005) 1.27
Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res (2003) 1.26
Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol (2009) 1.25
Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res (2007) 1.25
A Rasch and factor analysis of the Functional Assessment of Cancer Therapy-General (FACT-G). Health Qual Life Outcomes (2007) 1.19
Mining the archival formalin-fixed paraffin-embedded tissue proteome: opportunities and challenges. Mol Biosyst (2008) 1.18
The clinical value of quality of life assessment in oncology practice-a qualitative study of patient and physician views. Psychooncology (2008) 1.18
CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol (2008) 1.17
Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. Exp Cell Res (2005) 1.13
Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer (2006) 1.12
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res (2011) 1.12
Psychosocial care for cancer patients in primary care? Recognition of opportunities for cancer care. Fam Pract (2004) 1.11
Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am J Pathol (2002) 1.10
Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics (2006) 1.10
Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial. Eur J Cancer (2010) 1.09
Impact of patient-reported outcomes in oncology: a longitudinal analysis of patient-physician communication. J Clin Oncol (2011) 1.09
Proteomic analysis of formalin-fixed paraffin-embedded renal tissue samples by label-free MS: assessment of overall technical variability and the impact of block age. Proteomics Clin Appl (2013) 1.08
Renal cancer biomarkers: the promise of personalized care. BMC Med (2012) 1.08
Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations. J Proteome Res (2010) 1.07
Integrated multi-level quality control for proteomic profiling studies using mass spectrometry. BMC Bioinformatics (2008) 1.04
Banking of clinical samples for proteomic biomarker studies: a consideration of logistical issues with a focus on pre-analytical variation. Proteomics Clin Appl (2010) 1.04
A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. Proteomics (2011) 1.02
NMR structure of a bifunctional rhodamine labeled N-domain of troponin C complexed with the regulatory "switch" peptide from troponin I: implications for in situ fluorescence studies in muscle fibers. Biochemistry (2003) 1.02
Identification of novel VHL target genes and relationship to hypoxic response pathways. Oncogene (2005) 1.01
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res (2011) 1.00
Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun (2005) 0.99
Bifunctional rhodamine probes of Myosin regulatory light chain orientation in relaxed skeletal muscle fibers. Biophys J (2004) 0.98
Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer (2005) 0.96
Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival. Clin Cancer Res (2008) 0.96
Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One (2012) 0.95
Proteomic analysis of increased Parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function. Proteomics (2009) 0.94
Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics (2006) 0.92
The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res (2003) 0.92
Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr Relat Cancer (2014) 0.92
Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. Proteomics (2009) 0.91
Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder. J Pathol (2002) 0.90
Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int (2013) 0.90
Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model. Proteomics (2009) 0.89